Form 4: Bolt Biotherapeutics CEO Boosts Stake

William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, increased his direct beneficial ownership by acquiring 125 shares via an ESPP and receiving a 40,000-unit restricted stock award.

Summary

• William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, reported changes in his beneficial ownership of common stock.
• On June 6, 2025, Quinn acquired 125 shares of common stock at a price of $5.492 per share through the company's Employee Stock Purchase Plan (ESPP).
• On October 22, 2025, Quinn received an award of 40,000 restricted stock units (RSUs) for no consideration.
• Each restricted stock unit represents the right to receive one share of common stock upon settlement.
• Following these transactions, Quinn directly beneficially owns a total of 42,188 shares of common stock.
• The 40,000 restricted stock units are scheduled to vest in full on September 15, 2026, contingent on continued employment through that date.

Sentiment

Score: 7

Explanation: The filing indicates increased insider ownership by a key executive through both a personal purchase (ESPP) and a substantial equity award (RSUs). This generally signals management confidence in the company's future prospects and aligns executive incentives with shareholder interests, which is a positive indicator.

Positives

• Increased insider ownership by a key executive (President, CEO, and CFO) signals confidence in the company's future.
• The award of 40,000 restricted stock units aligns management's interests with long-term shareholder value.
• Participation in the Employee Stock Purchase Plan (ESPP) demonstrates personal investment by the executive.

Negatives

• The restricted stock units have a future vesting date (September 15, 2026), meaning the shares are not immediately available to the executive.

Risks

• The vesting of the 40,000 restricted stock units is contingent on William P. Quinn's continued employment through September 15, 2026.

Future Outlook

The 40,000 restricted stock units awarded to William P. Quinn are scheduled to vest in full on September 15, 2026, provided he remains employed by Bolt Biotherapeutics through that date.

Industry Context

Executive compensation packages in the biotechnology sector frequently include equity awards such as restricted stock units (RSUs) to incentivize long-term performance and align management interests with shareholder returns. Employee Stock Purchase Plans (ESPPs) are also common benefits offered to employees, including executives, allowing them to purchase company stock at a discount.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is a standard practice across the biotech and broader technology industries, similar to companies like Amgen or Gilead Sciences, which use equity awards to retain talent and motivate performance.
• The Employee Stock Purchase Plan (ESPP) offering is also a common benefit, comparable to those offered by many publicly traded companies, including those in the pharmaceutical and tech sectors, encouraging broad employee ownership.
• The specific vesting schedule (full vesting on a future date) is typical for RSU awards, designed to ensure executive retention and long-term commitment, aligning with practices seen at peer companies.

Stakeholder Impact

• Shareholders: Increased insider ownership can be viewed positively, suggesting management's belief in the company's value and aligning their interests with long-term shareholder returns.
• Employees: The existence of an Employee Stock Purchase Plan (ESPP) indicates a benefit available to employees, potentially fostering a sense of ownership.
• Management: The restricted stock unit award provides a significant long-term incentive for the President, CEO, and CFO, contingent on continued employment.

Next Steps

• Continued employment of William P. Quinn through September 15, 2026, for the full vesting of 40,000 restricted stock units.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, William P. Quinn, Form 4, insider transaction, beneficial ownership, common stock, ESPP, restricted stock units, RSU, executive compensation, biotech